For discussion: live attenuated vaccines for group B meningococcus.
Current attempts at preventing infections caused by group B Neisseria meningitidis are largely directed on generating immune responses to outer membrane proteins or the lipopolysaccharide of this organism. We suggest an alternative approach: the use of a live, attenuated strain of Neisseria meningitidis which could be delivered mucosally to elicit both local and systemic immune responses.
Tang
C
C
University Department of Paediatrics, John Radcliffe Hospital, Oxford, UK. christoph.tang@paediatrics.oxford.ac.uk
Moxon
R
R
Levine
M M
MM
D001428:Bacterial Vaccines / Q000009:adverse effects / Q000302:isolation & purification* / Q000494:pharmacology; D006801:Humans; D008589:Meningococcal Infections / Q000276:immunology / Q000517:prevention & control; D022401:Meningococcal Vaccines; D009345:Neisseria meningitidis / Q000145:classification* / Q000276:immunology* / Q000472:pathogenicity; D012449:Safety; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000302:isolation & purification / Q000494:pharmacology